Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ ...

Artificial intelligence dominated headlines in 2023 and 2024 with generative text, image synthesis, and autonomous agents.

ENFLONSIA is the first and only RSV preventive option in the European Union for administration to infants without the need for weight-based dosingRAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: ...

This approval marks an important new chapter in Merck’s long-standing commitment to research and discovery for people living ...

Merck , known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved ENFLONSIAtm (clesrovimab) for the prevention of respiratory syncytial virus ...

Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ ...

CNW/ - Health Canada has granted a Notice of Compliance (NOC) for Saphnelo® (anifrolumab injection) for subcutaneous self-administration via a ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUS ...

But the underlying principle is the same: tragedies can be measured and compared; suffering is quantifiable. To do this, ...

Blood-pressure reduction is the only proven treatment to prevent stroke. Whether a single pill that combines three ...

Filspari is now indicated for patients with focal segmental glomerulosclerosis without nephrotic syndrome to target significant proteinuria reduction.

On Jan 5, 2026, the Acting Director of the US Centers for Disease Control and Prevention (CDC) signed a decision memorandum from the heads of the National Institutes of Health, the Centers for ...